ESC 365 - Beneficial effects of SGLT2 inhibitors in patients with heart failure and kidney disease – What and why?

HFA Premium Access

Beneficial effects of SGLT2 inhibitors in patients with heart failure and kidney disease – What and why?

Session: Heart failure - Improving clinical outcomes in special populations

Topic: Heart Failure Association (HFA)

Speaker: Professor J. Tamargo (Madrid, ES)

Event: Heart Failure 2023

Congress Presentation

Add to my library

About the speaker

Professor Juan Tamargo

Complutense University of Madrid, Madrid (Spain)

15 presentations

3 followers

3 more presentations in this session

Advances in heart failure prevention: development of miRNA therapeutics for cardioprotection

Speaker: Professor P. Ferdinandy (Budapest, HU)

Pharmacological management of patients with worsening heart failure

Speaker: Doctor D. Tomasoni (Brescia, IT)

Prevention of HF with special populations: the case of obesity, diabetes, and CKD

Speaker: Doctor B. Moura (Porto, PT)

Access the full session

Heart failure - Improving clinical outcomes in special populations

Speakers: Professor J. Tamargo, Professor P. Ferdinandy, Doctor D. Tomasoni, Doctor B. Moura

About the event

Heart Failure 2023

20 May - 23 May 2023

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources